Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease
- About the CF Foundation
- Public Policy
- Health Care Reform
- Our Research Approach
- Our Advocacy Work
- Clinical Trials
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Genetic Therapies
- Drug Pipeline
- CFTR Modulators
- Care Centers
- North American CF Conference
- Coronavirus (COVID-19)
- Get Involved
- Infection Prevention and Control
- Adult Care
- Patient Assistance
- Researcher Resources
- (-) Advocacy
Foundation and Legislative Supporters Pushed for Bill
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
Eight Patient/Consumer Groups Urge Senate to Start Over
Twelve patient/consumer groups urge senate to reject the bill.
The legislation would impact the health care coverage of millions of Americans, including people living with cystic fibrosis.
Responding to the U.S. Department of Health and Human Services final rule on short-term, limited-duration insurance plans, the Cystic Fibrosis Foundation joined 26 other nonpartisan patient and consumer groups to voice concern that these plans will split the market and jeopardize access to affordable, adequate health care for people living with pre-existing conditions.